Sign up United Kingdom
Proactive Investors - Run By Investors For Investors
Why invest in TUMT?
Tumour Trace Limited: THE INVESTMENT CASE
INVESTMENT OVERVIEW

Tumour Trace boss wants to make early cancer screening “available for everybody everywhere at a cost everyone can afford”

The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system
Cancer cells
INVESTMENT OVERVIEW: TUMT The Big Picture
Tumour Trace is looking to the crypto-currency markets to fund further development, with sister operation Lancor Scientific is aiming to carry out an initial coin offering

Aamir Butt doesn’t lack ambition. “I want to make early cancer screening available for everybody everywhere at a cost everyone can afford,” says the chief executive of Tumour Trace (PRIVATE-UK:TUMT), a fledgling med-tech firm.

Simple when you say it quickly; more difficult when you have to deliver on those words.

WATCH: Lancor Scientific’s Darbyshire: “It’s the only way we’re going to kill cancer”

I think I might have sniggered had Butt delivered this line up-front. He didn’t; he let the technology do the talking.

And what became apparent from the outset is that Butt and his team at Nottingham-based Tumour Trace have made an impressive fist of developing the OMIS cancer detection system.

OMIS stands for Opto-magnetic Imaging Spectroscopy. It was the brainchild of Professor Djuro Koruga, the company’s chief scientific officer, and emanates from his research at the University of Belgrade.

Put simply, the device detects the minute electromagnetic changes that occur in tissue as cancer emerges and develops. “It allows us to not only characterise the tissue so we know what stage the cancer might be at, but also allows us to detect pre-cancer,” says Butt.

A sample can be garnered using minimally invasive techniques and read-outs emerge in ‘near’ real-time (less than 30 seconds), while the technology itself is “cancer agnostic”. And it’s cheap as well. Butt hopes in time to be able to offer screening for as little as ten pounds a pop.

Delineation between screening and diagnostics

It is at this point I should make the delineation between screening and diagnostics as it is key to this particular story.

Screening is a pre-emptive process that sees tens of thousands of people annually assessed for the early signs of breast, cervical and prostate cancers.

It saves many lives but it isn’t an exact science with around a 60% strike rate. In other words, there are a lot of false positives.

OMIS is a far more reliable predictor, detecting cancer in 90% of cases. “That puts us right at the top end for screening,” says Butt.

However, for it to be a proper diagnostic tool it needs to rival the gold standard in this arena – biopsy. So the aim is to refine OMIS to the point where it provides the correct diagnosis around 97% of the time.

Tumour Trace is looking to the crypto-currency markets to fund further development, although it is not tapping investors directly.

Medici initial coin offering

Sister operation Lancor Scientific (PRIVATE-UK:LANCO) is aiming to carry out an initial coin offering (ICO) by issuing Medici, a new currency based on Ethereum.

The ICO has a soft cap of $5mln, which would be more than enough to complete the 4,000-person trial set to take place in Germany, Austria and the UK.

The hard cap is an impressive $50mln, which will allow Butt and his team to do a lot more than a trial.

A seed round launched earlier this week is close to bringing the targeted $1-$2mln and Butt says there is no shortage of demand from those who see the merits of holding Medici.

The early adopters will subscribe in the hope the coin value increases along with the size of the business. Further down the line Medici will be used to pay for cancer diagnostic services that will secure holders an immediate 20% discount.

While there may be a ready market for the currency, what about the Tumour Trace product?

Well, to supplant screening services in developed countries such as the UK OMIS will have to be palpably cheaper than what is currently in place. And it is.

However, large bureaucracies such as the NHS are glacial in their approach to change – particularly when a service is working.

Emerging economies offer most immediate prospect of success

And while there has been interest from Europe, common sense dictates the emerging economies offer the most immediate prospect of success.

“In countries where they don’t have screening programmes the opportunity is there to embed your technology from an early stage of the investment cycle,” agrees Butt.

WATCH: Lancor Scientific 'revolutionising the way people have access to cancer screening'

The initial commercial plan is to sell OMIS units, or charge a lower fee and take a payment per test; however, there are grander ambitions down the road.

Butt wants to develop multi-cancer diagnostic centres where the public can pay to be screened privately. You’d imagine the demand for such a service would be huge.

As mentioned earlier, ICO itself isn’t being done by Tumour Trace itself, but via a company called Lancor Scientific, which encapsulates the far broader vision of Butt and his team.

The Lancor platform is the developer and holder of blockchain technology that will support Tumour Trace.

It is simultaneously capable of issuing contracts, garnering access to patient records and collating clinical data – and much more besides.

Harnessing the power of artificial intelligence it could be a treasure trove of data.

Down the line, other specialist testing companies could be plugged into the platform.

Properly funded, it becomes easier to see how Lancor could help Butt and his colleagues achieve that lofty goal of cheap cancer screening for all.

Join our Crypto, Blockchain and Cannabis Telegram group here
View full TUMT profile View Profile

Tumour Trace Limited Timeline

Related Articles

Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system
woman at a microscope
August 02 2018
Currently undergoing phase III clinical trials, AP101 is being developed to treat Epidermolysis Bullosa, a condition which occurs prominently in children and makes skin fragile to even the faintest touch
scientist in lab
August 31 2018
While the data bodes well for MTD201, Midatech is most excited by the validation of its Q-Sphera sustained release technology, which it is using in some of its other compounds

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use